Accordingly, we speculated that GC patients with high BCAT1 expression may benefit more from treatment with inhibitors of the PI3K/AKT/mTOR pathway, such as everolimus, temsirolimus, buparlisib, and perifosine, which have been approved for anticancer therapy or are being tested in early clinical trials (Polivka and Janku, 2014; Singh et al., 2015). This evidence concerns the gene MTOR and gastric cancer.